Table 1 Clinical and laboratory characteristics of study patients (n = 30)
No | % | |
|---|---|---|
Muscle power | ||
Grade 0 | 1 | 3 |
Grade 1 | 2 | 7 |
Grade 2 | 2 | 7 |
Grade 3 | 10 | 33 |
Grade 3–4 | 5 | 17 |
Grade 4 | 10 | 33 |
Dyspnea | ||
Free | 15 | 50 |
Mild | 6 | 20 |
Moderate | 5 | 17 |
Severe | 4 | 13 |
Fatigue | ||
No | 10 | 33 |
Yes | 20 | 67 |
Dry cough | ||
No | 15 | 50 |
Yes | 15 | 50 |
Skin affection | ||
No | 10 | 33 |
Yes | 20 | 67 |
Mild | 10 | 33 |
Moderate | 5 | 17 |
Severe | 5 | 17 |
Skin score | ||
Min.–Max | 10.0–122.0 | |
Mean ± SD | 85.48 ± 26.49 | |
PFT | ||
FVC (L) Mean ± SD | 1.81 ± 0.88 | |
FVC% Mean ± SD | 54.0 ± 21.98 | |
FEV1 (L) Mean ± SD | 1.83 ± 0.65 | |
FEV1% Mean ± SD | 64.27 ± 18.24 | |
CPk (U/L) | ||
Min.–Max | 880–10,000 | |
Mean ± SD | 7007.0 (1160–8500) | |
LDH (U/L) | ||
Min.–Max | 350.0–1670.0 | |
Mean ± SD | 931.84 ± 223.19 | |
ALT (U/L) | ||
Min.–Max | 45.0–343 | |
Median (IQR) | 89.50 (60–167) | |
AST (U/L) | ||
Min.–Max | 46.0–290 | |
Median (IQR) | 88.50 (60–220) | |
KL-6 (U/ML) | ||
Min.–Max | 75.0–1300 | |
Median (IQR) | 744.50 (130.0–905.0) | |
Anti-Jo-1 (AU/ML) | ||
Negative | 22 (73%) | |
Positive | 8 (27%) | |
ANA( IU/ML) | ||
Negative | 10 (33) | |
Positive | 20 (67%) | |